Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study

Overview of attention for article published in Frontiers in immunology, October 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 4 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 50,094 followers.

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study: Survival is generally poor for Chinese patients with advanced melanoma because of high rates of acral and mucosal melanoma and… #immunology https://t.co/9

14 Oct 2022

Reply Repost Favourite

New Research: Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study: Survival is generally poor for Chinese patients with advanced melanoma because of high rates of acral and mucosal melanoma and… https://t.co/

12 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.